Tekla Life Sciences Investors: management transactions · United States · SEC (Form 4)

About Tekla Life Sciences Investors

Tekla Life Sciences Investors is a U.S.-listed closed-end fund traded on the NYSE under ticker HQL. For French-speaking investors, it should be viewed less as an operating company and more as a specialized listed investment vehicle focused on life sciences. The fund is organized as a Massachusetts business trust, was formed on February 20, 1992, and commenced operations on May 8, 1992. Its stated objective is long-term capital appreciation through investment primarily in life sciences companies in the United States and abroad. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884121/000110465922125155/tm2225213d1_ncsr.htm)) The fund’s mandate spans the core growth areas of healthcare innovation: biotechnology, pharmaceuticals, diagnostics, managed care, medical devices, healthcare information technology, supplies and services, and, when the adviser sees scientific upside, agriculture and environmental management. HQL is designed to invest mainly in equity and related securities of companies expected to benefit from scientific advances. It also has the flexibility to allocate up to 40% of net assets to restricted securities, including public and private companies, giving the portfolio access to crossover opportunities that are not typically available in plain-vanilla listed funds. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884121/000110465922125155/tm2225213d1_ncsr.htm)) From a competitive standpoint, HQL stands out for its concentrated sector exposure and active management style in a universe where outcomes are highly dispersed. The fund looks for companies with strong market positions, recognized technical expertise, experienced management teams, and the ability to self-fund growth or secure outside capital. That framework creates meaningful upside participation in innovation cycles, clinical catalysts, M&A activity, and multiple expansion, but it also implies higher volatility and greater sector-specific risk than a diversified multi-sector fund. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884121/000110465922125155/tm2225213d1_ncsr.htm)) Historically associated with Tekla Capital Management, the fund was transferred to abrdn Inc. effective at the close of business on October 27, 2023, while retaining the HQL ticker and its life sciences focus. In the latest annual report available, the fund reported a 22.75% NAV total return and a 35.94% market price total return for the fiscal year ended September 30, 2024, indicating a favorable period for healthcare and biotech exposure. Investors should note, however, that as a closed-end fund, HQL may trade at either a premium or a discount to NAV. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884121/000110465924126672/tm2430035d6_ncsr.htm)) As a NYSE-listed vehicle in the United States, Tekla Life Sciences Investors is best understood as a targeted public-market gateway to life sciences rather than a conventional industrial business. Its appeal lies in professionally managed exposure to a structurally attractive sector supported by demographic tailwinds, medical innovation, and ongoing healthcare M&A activity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884121/000110465922125155/tm2225213d1_ncsr.htm))